IE 11 is not supported. For an optimal experience visit our site on another browser.

China Nuokang Bio-Pharmaceutical Inc. to Report Third Quarter 2010 Financial Results

BEIJING, Nov. 10, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release third quarter financial results on Wednesday, November 17, 2010, after market close.
/ Source: GlobeNewswire

BEIJING, Nov. 10, 2010 (GLOBE NEWSWIRE) -- China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) ("Nuokang" or the "Company"), a leading China-based biopharmaceutical company focused on the research, development, manufacture, marketing and sales of hospital-based medical products, today announced that the Company plans to release third quarter financial results on Wednesday, November 17, 2010, after market close.

The Company will hold a conference call at 8:00 am ET on Thursday, November 18, 2010 to discuss third quarter 2010 results. Listeners may access the call by dialing:

A telephone replay will be available beginning two hours after the conclusion of the call and will be available through November 25, 2010. Listeners may access the replay by dialing:

A webcast will also be available through the Company's website www.nkbp.com. 

About China Nuokang Bio-Pharmaceutical Inc.

China Nuokang Bio-Pharmaceutical Inc. (Nasdaq:NKBP) is a leading biopharmaceutical company in China focused on the research, development, manufacture, marketing and sales of hospital-based medical products. The Company provides a diversified portfolio of products across more than 2,400 hospitals in China. Nuokang's principal products include Baquting®, China's leading hemocoagulase product by market share, and Aiduo®, a cardiovascular stress imaging agent. The Company's product pipeline includes product candidates under development in hematological, cardiovascular and cerebrovascular disease diagnosis, treatment and prevention. Please visit www.nkbp.com for more information. 

CONTACT: ICR, LLC In the U.S.: Ashley M. Ammon Christine Duan 1-646-277-1227 In China: Wen Lei Zheng 86-10-6599-7968